TKAI ALERT: Rosen Law Firm Reminds Tokai Pharmaceuticals,

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
TKAI ALERT: Rosen Law Firm Reminds Tokai Pharmaceuticals, Inc. Investors of Important September 30 Deadline in Class Action - TKAI

NEW YORK, Sept. 16, 2016 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Tokai Pharmaceuticals, Inc. securities (NASDAQ: TKAI ) from June 24, 2015 through July 25, 2016, both dates inclusive (the “Class Period”) of the important September 30, 2016 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Tokai Pharmaceuticals investors under the federal securities laws.

To join the Tokai Pharmaceuticals class action, go to the firm’s website at http://rosenlegal.com/cases-928.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email pkim@rosenlegal.com or kchan@rosenlegal.com for more information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) there were significant structural problems with the trial design for Tokai Pharmaceuticals’ pivotal Phase 3 galeterone study, ARMOR3-SV; (2) in turn, ARMOR3-SV was unlikely to succeed in meeting its primary endpoint; (3) consequently, commercialization of galeterone was less likely and/or imminent than Tokai Pharmaceuticals had led investors to believe; and (4) as a result, defendants’ statements about Tokai Pharmaceuticals’ business and operations were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 30, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://rosenlegal.com/cases-928.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com . Attorney Advertising.  Prior results do not guarantee a similar outcome.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm .

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 lrosen@rosenlegal.com pkim@rosenlegal.com kchan@rosenlegal.com www.rosenlegal.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Jersey Teamsters Stand Firm for Fair Health Worker Deal

Updated Category News Views 117

ImageCare Workers Ready to Strike Normally, when we hear about health care, we're pretending it’s this well-oiled machine. But here we are, witnessing techs and aides at ImageCare gearing up to strike for the first time. Sussex County’s finest have had it up to their ears negotiating for a union contract that doesn’t treat them like an afterthought. Two-Year...

Continue Reading
Tech Job Market Surges with AI and IT Skills Spike

Updated Category News Views 92

Alright, folks, though we're not drowning in champagne just yet, there's a promising uptick in October's tech employment, signaling a rebound or at least some relief for tech pros and market watchers. CompTIA's numbers show a boost of 7,200 jobs in the tech industry while IT occupations expanded by 26,000 slots. That's no small feat when the general job scene elsewhere...

Continue Reading
CorelDRAW's Flexibility: A Designer's One-Time Buy?

Updated Category News Views 66

CorelDRAW: A Design Powerhouse Without Recurring Bills? Every so often, a software option comes along that piques my interest, and right now, it's CorelDRAW Graphics Suite. Consumer365 has shone a light on this nifty tool for its one-time purchase model—a breath of fresh air in the age of endless subscriptions that seem to drain more than enthusiasm as the months roll...

Continue Reading
Rutter Mills Expands Turkey Giveaway to Two Cities

Updated Category News Views 13

An Extra Helping of Community Spirit Rutter Mills is back on the scene again this Thanksgiving, slinging out a thousand turkeys to show their appreciation for the community they’ve called home since 1959. This initiative is the second iteration of their Turkey Drop, an event that's set to become a cherished tradition for years to come. Last year's event only teased the...

Continue Reading
WIC 2026: Global Connectivity and Cyber Futures

Updated Category News Views 144

Connectivity Takes Center Stage in Wuzhen When you throw 1,800 movers and shakers into a room focused on the future of the internet, sparks are gonna fly. That's exactly what's going down at the 2026 World Internet Conference in Wuzhen, China. Brass tacks: this ain't just another snooze-fest. The theme this year screams significance—'Open Source and Openness, Joined...

Continue Reading
VS Pharmtech Enhances Cancer Drug Efficiency, Eyes IPO

Updated Category News Views 86

Revolutionizing Cancer Care, One Dose at a Time Now, here's a twist worth chewing over your morning coffee: VS Pharmtech isn't concocting some newfangled miracle drug but is instead jazzing up the old ones. Their creation, VS-101, isn't just another treatment—it's a radiosensitizer designed to make existing therapies more potent without the toxic baggage. The Science...

Continue Reading
Pre-Owned Jet Inventory Rises; Price Trends Unclear

Updated Category News Views 83

October's Pre-Owned Aircraft Inventory: A Mixed Bag Nothing like leafing through October's data on pre-owned jets and feeling your stomach do that weird flip-flop. Inventory's nudging up, but it's still on its knees compared to last year's numbers. According to Sandhills Global's fresh aviation market reports, we got an increase in what's available on platforms like...

Continue Reading
212NYC Gala Celebrates Ad Industry's Human Touch

Updated Category News Views 98

The Advertising Gala with Heart When you toss nearly 300 advertising honchos into a room at Tribeca's Rooftop, you don't just get another bash; you get an industry checkpoint. This time, the 212NYC shindig on November 5, 2026, wasn't just about stroking egos. It was about spotlighting the soul in business, right when AI threatens to run wild with it. Navigating AI's...

Continue Reading
QORAI CORP's Q4 Nexus: A New AI Frontier

Updated Category News Views 51

Breakthrough in AI: Enter Q4 Nexus It's not every day you see a tech player emerge with something genuinely fresh—QORAI CORP is shaking up the scene with its Q4 Nexus platform. This isn't just another AI model upgrade. We're talking about a rethink of the very architecture we rely on to power these systems. Founder Robby Joshi's brainchild, Q4 Nexus, jazzes up the AI...

Continue Reading
Sass Magazine's 2026 COZY Issue Embraces Intentional Joy

Updated Category News Views 70

An Unexpected Shift in Sass's Seasonal Focus When you think November and December, it's easy to picture the hustle and bustle of holiday preparations—shopping, parties, running around. But toss all that hullabaloo out the window, because Sass Magazine has thrown a curveball for their 2026 release. They're steering the ship towards the calm, with their COZY Issue shaping...

Continue Reading

Top 5 Most Recently Viewed Articles

Relmada Therapeutics Announces Q3 2025 Results Call Details

Updated Category News Views 183

Relmada Therapeutics Confirms Conference Call for Financial Results Relmada Therapeutics, Inc. (NASDAQ: RLMD), a pioneering biotechnology firm focused on innovative therapies for oncology and central nervous system disorders, has officially scheduled a conference call and webcast. This event will be held on an upcoming Thursday, launching at 4:30 PM ET, as they present...

Continue Reading
Spotify SPOT: P/E Dilemma in a Market Freefall

Updated Category News Views 179

Spotify Technology Inc. (NYSE:SPOT) is catching some chatter today, showing a 2.51% spike to hit $469.87. But don’t let that number fool you; over the past month, this stock has slipped 8.11%, and if you squint at the longer horizon, it’s down a staggering 26.90% year-over-year. So, what’s really going on here? Are shareholders holding onto a ticking time bomb or...

Continue Reading
Senseonics Unveils New Era for Diabetes Care with Eversense 365

Updated Category News Views 183

Transforming Diabetes Management with Eversense 365 Senseonics Holdings, Inc. is ushering in a new age of diabetes care with its innovative Eversense 365 Continuous Glucose Monitoring (CGM) system. This groundbreaking technology is designed for individuals living with diabetes, providing them with an option that extends glucose monitoring capabilities up to one year. This...

Continue Reading
Upland Mutual Insurance Achieves Positive Rating Outlook

Updated Category News Views 148

Positive Rating Outlook for Upland Mutual Insurance Upland Mutual Insurance, Inc. has recently received significant recognition from AM Best, which has revised its outlook to positive from stable. Along with this positive shift, AM Best has also affirmed the Financial Strength Rating of B++ (Good) and the Long-Term Issuer Credit Rating of 'bbb+' (Good) for Upland. This...

Continue Reading
Arencibia & Co. Unveils Unique Luxury Home Projects

Updated Category News Views 186

Introducing Arencibia & Co. Arencibia & Co. has officially launched, marking a significant step in the luxury residential construction landscape. The firm, led by industry veteran Joel Arencibia, is already making waves with two major projects: a stunning private-island residence and a luxurious home situated on Upper East Side Park Avenue. These projects are a testament...

Continue Reading